CHMP recommends Vipdomet (Takeda) for Type 2 Diabetes
On 25 July 2013, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Vipdomet, from Takeda, 12.5 mg / 1000 mg and 12.5 mg / 850 mg, film-coated tablet intended for the treatment of Type 2 Diabetes Mellitus in adults. The active substances of Vipdomet are alogliptin/metformin, a combination of two oral blood glucose-lowering products (ATC code: A10BD13).
Alogliptin is a dipeptidyl peptidase 4 (DPP 4) inhibitor which reduces the cleavage and inactivation of the active (intact) form of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), producing an elevation of incretin concentrations that leads to an enhancement of glucose-dependent insulin secretion and a reduction in glucagon release. Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and, therefore, does not produce hypoglycaemia. It is thought to act via various mechanisms, including decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilisation.
Alogliptin plus metformin is FDA approved as Kazano.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins